期刊文献+

鲍曼不动杆菌多位点序列分型与抗生素耐药表型的关系 被引量:4

下载PDF
导出
摘要 目的对鲍曼不动杆菌菌株进行分子流行病学分型及耐药性分析,为临床防控提供指导。方法收集非重复鲍曼不动杆菌42株,采用多位点序列分型(MLST)进行分子流行病学分型,e BURST分析菌株亲缘性,纸片扩散法进行药敏试验。结果 42株鲍曼不动杆菌被分为10个ST型,其中ST195及ST208最常见,占总数的69.0%,e BURST分析提示主要流行克隆为CC92。根据纸片药敏结果,菌株对多黏菌素B的敏感性最高为100%,其余抗生素的敏感率均小于30%,42株菌株可分为多重耐药(MDR)菌株11株,广泛耐药(XDR)菌株31株。优势克隆CC92与非CC92的MDR、XDR菌株的比例差异无统计学意义(P=0.676)。结论鲍曼不动杆菌CC92广泛流行,CC92与非CC92菌株的耐药性无差别,CC92的成功流行可能更依赖于对医院环境的高度适应性。
出处 《广东医学》 CAS 北大核心 2015年第12期1818-1821,共4页 Guangdong Medical Journal
基金 广州市医药卫生科技项目(编号:20151A011004)
  • 相关文献

参考文献15

  • 1陈佰义,何礼贤,胡必杰,倪语星,邱海波,石岩,施毅,王辉,王明贵,杨毅,张菁,俞云松.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85. 被引量:848
  • 2PELEG A Y, SEIFERT H, PATERSON D L. Acinetobacter bau- mannii: Emergence emergence of a suceessfal Pathogenpathogen [J]. Clin Microbiol Re,;, 2008, 21(3) : 538-582.
  • 3KARAH N, SUNDSFJORD A, TOWNER K, et al. Insights into the global molecular epidemiology of earbapenm non - susceptible clones of Acinetobacter baumannii[ J]. Drug Resist Updat, 2012, 15(4) : 237 -247.
  • 4杨潮,颜焱锋,王桂琴,谭亚芳.鲍曼不动杆菌多重耐药中国分离株的多位点序列分型及种群结构[J].中华预防医学杂志,2011,45(8):727-731. 被引量:5
  • 5LI Y J, PAN C Z, ZHAO Z W, et al. Effects of a combination of amIodipire and imipertem on 42 clinical isolates f Aeiethaeter baumannii obtained from a teaching hospital in Guangzhou, China [J]. BMC Infectious Diseases, 2013, 13: 548.
  • 6ZHONG Q, XU W, WU Y, et at. Clonal spread of carbapenem non - susceptible Aeinetobacter baumannii in an intensive care unit in a teaching hospital in China[ J]. Ann Lab Mcd, 2012, 32(6) : 413 -419.
  • 7RUNNEGAR N, SIDJABAT H, GOH H M, et al. Molecular epi- demiology of multidmg - resistant Acinetobacter baumannii in a single institution over a 10 -year period [ J]. J Clin Microbiol, 2010, 48(11) : 4051 -4056.
  • 88ARTUAL S G, SEIFERT H, HIPPLER C, et al. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii[ J ]. J Clin Microbiol, 2005, 43(9) : 4382 -4390.
  • 9Clinnical and Laboratory Standards Institute. M[00 - $22 Perform- ance standards for antimievobial susceptibility testing, Twenty - Second informational supplemem [ S ]. Wayne PA : Clinical and Laboratory Standardslnstitute, 2012.
  • 10胡继红,张楠,高振祥,高屹,张然,艾效曼,许宏涛,陶凤荣,宣天芝,胡云建.头孢哌酮-舒巴坦药敏纸片中舒巴坦量对药敏结果的影响[J].中华检验医学杂志,2010,33(3):231-235. 被引量:19

二级参考文献78

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:241
  • 2张小江,徐英春,俞云松,杨青,汪复,朱德妹,倪语星,孙景勇,孙自镛,简翠,胡云建,艾效曼,张泓,李万华,贾蓓,黄文祥,王传清,王爱敏,魏莲花,吴玲,卓超,苏丹虹,张朝霞,季萍,徐元宏,熊自忠,沈继录,单斌,杜艳.2009年中国CHINET鲍曼不动杆菌细菌耐药性监测[J].中国感染与化疗杂志,2010,10(6):441-446. 被引量:137
  • 3王辉,郭萍,孙宏莉,杨启文,陈民钧,朱元珏,徐英春,谢秀丽.碳青霉烯类耐药的不动杆菌分子流行病学及其泛耐药的分子机制[J].中华检验医学杂志,2006,29(12):1066-1073. 被引量:237
  • 4Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother, 1999, 43:738-744.
  • 5Bradford P. Tigecycline: a first in class glycylcycline. Clin Micro Newsl, 2004,26:163-168.
  • 6Felmingham D. Tigecycline-the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline. J Chemother, 2005,17 Suppl 1:5-11.
  • 7Chopra I, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother,1992 ,29 :245-277.
  • 8Schnappinger D, Hillen W. Tetraeyclines: antibiotic action, uptake, and resistance mechanisms. Arch Mierobiol, 1996, 165:359-369.
  • 9Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drugdirected Fe^2 + cleavage of 16S rRNA. J Antimicrob Chemother, 2004, 53:592-599.
  • 10Olson MW, Ruzin A, Feyfant E, et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother, 2006,50 : 2156 -2166.

共引文献931

同被引文献23

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部